AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 11 analysts
Fundamentals
Fundamentals institutional score is 26 using growth durability 25.9.
Valuation
Valuation institutional score is 32 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 56 using mean target upside 4.6%; dispersion penalty 15.5; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 36 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. Available evidence provides partial support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 81.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.32). Confidence: 67%.
Live forward EPS implies next-12-month EPS of ₹19.11. Applying the stock's normalized valuation corridor produces a fair range of ₹1,068.44 to ₹1,927.63, with base value near ₹1,485.42 (+71.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹19.11
Forward P/E
45.4x
Base Fair Value
₹1,485.42
Fair Range
₹1,068.44 - ₹1,927.63
Upside To Base
+71.3%
Estimate Source
Live forward EPS
Growth Estimate
-81.4%
5Y Average
60.44
Current
140.96
Overvalued
100.87
Undervalued
55.91
5Y Average
20.41
Current
47.47
Overvalued
30.18
Undervalued
9.72
5Y Average
6.67
Current
15.50
Overvalued
9.86
Undervalued
3.18
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 68.3x Fair | -14% vs avg | +1.4% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 158.6x Premium | +99% vs avg | +10.2% |
DR AGARWALS HEALTH CARE L AGARWALEYEHospitals & Diagnostic Centres | +26.0% | 6.7% | 116.0x Premium | +46% vs avg | +21.5% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 68.7x Fair | -14% vs avg | +6.9% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.8x Undervalued | -42% vs avg | +6.8% |
DR. LAL PATH LABS LTD. LALPATHLABHospitals & Diagnostic Centres | +19.1% | 18.7% | 59.9x Undervalued | -25% vs avg | +20.0% |
RAINBOW CHILDRENS MED LTD RAINBOWHospitals & Diagnostic Centres | +33.2% | 15.7% | 53.9x Undervalued | -32% vs avg | +1.2% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 64.8x Undervalued | -18% vs avg | +23.2% |
ASTER DM QUALITY CARE LTD trades at a premium (139.2x vs peer avg 79.5x), implying higher growth or quality expectations from the Hospitals & Diagnostic Centres cohort. Peers include FORTIS HEALTHCARE LTD, KRISHNA INST OF MED SCI L, DR AGARWALS HEALTH CARE L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹726 CrJun 2026Latest net profit
₹-14 CrJun 2026Latest EPS
₹-0.28Jun 2026Net margin
20.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 457 | 509 | 524 | 546 | 566 | 605 | 576 | 574 | 613 | 682 | 666 | 655 | 726 |
| Expenses + | 374 | 423 | 433 | 446 | 464 | 476 | 465 | 459 | 480 | 532 | 537 | 517 | 579 |
| Operating Profit | 83 | 86 | 92 | 100 | 101 | 129 | 111 | 115 | 134 | 150 | 129 | 138 | 147 |
| OPM % | 18% | 17% | 17% | 18% | 18% | 21% | 19% | 20% | 22% | 22% | 19% | 21% | 20% |
| Other Income + | 11 | 20 | 13 | 4 | 5,992 | 47 | 14 | 9 | 34 | 44 | 24 | -37 | -71 |
| Interest | 16 | 21 | 21 | 21 | 21 | 19 | 22 | 23 | 22 | 23 | 22 | 21 | 24 |
| Depreciation | 26 | 29 | 31 | 36 | 35 | 37 | 36 | 38 | 38 | 39 | 39 | 38 | 41 |
| Profit before tax | 53 | 57 | 53 | 47 | 6,037 | 120 | 68 | 63 | 108 | 132 | 91 | 43 | 11 |
| Tax % | 0% | -4% | 0% | 117% | 0% | 25% | 27% | 2% | 25% | 21% | 39% | 36% | 231% |
| Net Profit + | 53 | 59 | 53 | -8 | 6,008 | 90 | 50 | 61 | 81 | 105 | 55 | 27 | -14 |
| EPS in Rs | 1.06 | 1.18 | 1.06 | -0.16 | 120.28 | 1.80 | 1.00 | 1.22 | 1.56 | 2.02 | 1.06 | 0.53 | -0.28 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation